Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 1:13:948647.
doi: 10.3389/fimmu.2022.948647. eCollection 2022.

Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer

Xin Jin  1   2 , Zhaorui Liu  1 , Dongxiao Yang  1 , Kai Yin  1 , Xusheng Chang  1
Affiliations
Review

Recent Progress and Future Perspectives of Immunotherapy in Advanced Gastric Cancer

Xin Jin et al. Front Immunol. .

Abstract

As one of the most common forms of solid tumours, gastric carcinoma has been revealed as the third leading cause of death worldwide. The symptom of gastric cancer is usually not obvious and thus difficult to detect at earlier stages. Therefore, gastric cancer is already in the advanced stage once detected in patients, which has a poor prognosis due to ineffective therapies and multiple resistance. Recent advance in understanding the microenvironment of cancer has significantly promoted the development of immunotherapy for advanced gastric cancer. Immunotherapy can induce immune responses in gastric cancer patients thus leads to the destruction of cancer cells. In comparison of traditional therapy, immunotherapy has demonstrated robust efficacy and tolerable toxicity. Therefore, this novel strategy for treatment of advanced gastric cancer has gain increasingly popularity. In this review, we summarize recent progress of immunotherapy in advanced gastric cancer, such as immune check point inhibitors, adoptive cell therapy, VEGF inhibitors, cancer vaccines and CAR-T cell therapy. We highlight immunotherapies involved in clinical applications and discuss the existing challenges of current immunotherapies and promising strategies to overcome these limitations.

Keywords: CAR-T cell therapy; adoptive cell therapy; advanced gastric cancer; cancer vaccine; immune checkpoint inhibitor; immunotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Different types of immunotherapies in advanced gastric cancer. Immune checkpoint inhibitor, adoptive cell therapy, VEGF inhibitor, cancer vaccine and CAR-T cell therapy are the main types of immunotherapies for treatment of advanced gastric cancer.
See this image and copyright information in PMC

References

    1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Pineros M, et al. . Estimating the Global Cancer Incidence and Mortality in 2018: GLOBOCAN Sources and Methods. Int J Cancer (2019) 144(8):1941–53. doi: 10.1002/ijc.31937 - DOI - PubMed
    1. Hogner A, Moehler M. Immunotherapy in Gastric Cancer. Curr Oncol (2022) 29(3):1559–74. doi: 10.3390/curroncol29030131 - DOI - PMC - PubMed
    1. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. . Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer. J Clin Oncol (2011) 29(33):4387–93. doi: 10.1200/JCO.2011.36.5908 - DOI - PubMed
    1. Ajani JA, Lee J, Sano T, Janjigian YY, Fan D, Song S. Gastric Adenocarcinoma. Nat Rev Dis Primers (2017) 3:17036. doi: 10.1038/nrdp.2017.36 - DOI - PubMed
    1. Mellman I, Coukos G, Dranoff G. Cancer Immunotherapy Comes of Age. Nature (2011) 480(7378):480–9. doi: 10.1038/nature10673 - DOI - PMC - PubMed

Publication types